Xconomy | Boston - Business + Technology in the Exponential Economy

FDA Committee Votes in Favor of Dyax Lead Drug for Rare Blood Disease
Deux Deals for Dyax, Au Revoir for Vertex’s Boger, Grande Alliance for Idenix and GSK, & More Boston-Area Life Sciences News
Backchannelmedia Opens Revenue Channel, GSK to Shell Out Up to $450M for Idenix Drug, GI Dynamics Packs On $15M, & More Boston-Area Deals News
Dyax Shares Climb as Lead Drug Candidate Passes Trial
Dyax Hit With FDA Drug Delay

Drugs, Eye Disease, Life Sciences

Dyax and Fovea Strike Drug Pact

Ryan McBride 2/10/09

Biotech firm Dyax (NASDAQ:DYAX), based in Cambridge, MA, says that it has struck an exclusive license deal with French drug firm Fovea Pharmaceuticals to develop a version of Dyax’s lead drug ecallantide for eye diseases. Separately, Dyax is pursuing U.S. approval of ecallantide for a rare blood disease called hereditary angioedema (HAE). Last week an FDA panel recommended approval of the protein drug for HAE, and the agency is expected to decide whether to approve the drug by March 23.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.

Comments | Reprints | Share: